BACKGROUND: Harms and benefits of cancer screening depend on age and comorbid conditions, but reliable estimates are lacking. OBJECTIVE: To estimate the harms and benefits of cancer screening by age and comorbid conditions to inform decisions about screening cessation. DESIGN: Collaborative modeling with 7 cancer simulation models and common data on average and comorbid condition level-specific life expectancy. SETTING: U.S. population. PATIENTS: U.S. cohorts aged 66 to 90 years in 2010 with average health or 1 of 4 comorbid condition levels: none, mild, moderate, or severe. INTERVENTION: Mammography, prostate-specific antigen testing, or fecal immunochemical testing. MEASUREMENTS: Lifetime cancer deaths prevented and life-years gained (benefits); false-positive test results and overdiagnosed cancer cases (harms). For each comorbid condition level, the age at which harms and benefits of screening were similar to that for persons with average health having screening at age 74 years. RESULTS: Screening 1000 women with average life expectancy at age 74 years for breast cancer resulted in 79 to 96 (range across models) false-positive results, 0.5 to 0.8 overdiagnosed cancer cases, and 0.7 to 0.9 prevented cancer deaths. Although absolute numbers of harms and benefits differed across cancer sites, the ages at which to cease screening were consistent across models and cancer sites. For persons with no, mild, moderate, and severe comorbid conditions, screening until ages 76, 74, 72, and 66 years, respectively, resulted in harms and benefits similar to average-health persons. LIMITATION: Comorbid conditions influenced only life expectancy. CONCLUSION: Comorbid conditions are an important determinant of harms and benefits of screening. Estimates of screening benefits and harms by comorbid condition can inform discussions between providers and patients about personalizing screening cessation decisions. PRIMARY FUNDING SOURCE: National Cancer Institute and Centers for Disease Control and Prevention.
BACKGROUND: Harms and benefits of cancer screening depend on age and comorbid conditions, but reliable estimates are lacking. OBJECTIVE: To estimate the harms and benefits of cancer screening by age and comorbid conditions to inform decisions about screening cessation. DESIGN: Collaborative modeling with 7 cancer simulation models and common data on average and comorbid condition level-specific life expectancy. SETTING: U.S. population. PATIENTS: U.S. cohorts aged 66 to 90 years in 2010 with average health or 1 of 4 comorbid condition levels: none, mild, moderate, or severe. INTERVENTION: Mammography, prostate-specific antigen testing, or fecal immunochemical testing. MEASUREMENTS: Lifetime cancer deaths prevented and life-years gained (benefits); false-positive test results and overdiagnosed cancer cases (harms). For each comorbid condition level, the age at which harms and benefits of screening were similar to that for persons with average health having screening at age 74 years. RESULTS: Screening 1000 women with average life expectancy at age 74 years for breast cancer resulted in 79 to 96 (range across models) false-positive results, 0.5 to 0.8 overdiagnosed cancer cases, and 0.7 to 0.9 prevented cancer deaths. Although absolute numbers of harms and benefits differed across cancer sites, the ages at which to cease screening were consistent across models and cancer sites. For persons with no, mild, moderate, and severe comorbid conditions, screening until ages 76, 74, 72, and 66 years, respectively, resulted in harms and benefits similar to average-health persons. LIMITATION: Comorbid conditions influenced only life expectancy. CONCLUSION: Comorbid conditions are an important determinant of harms and benefits of screening. Estimates of screening benefits and harms by comorbid condition can inform discussions between providers and patients about personalizing screening cessation decisions. PRIMARY FUNDING SOURCE: National Cancer Institute and Centers for Disease Control and Prevention.
Authors: Gerrit Draisma; Rob Boer; Suzie J Otto; Ingrid W van der Cruijsen; Ronald A M Damhuis; Fritz H Schröder; Harry J de Koning Journal: J Natl Cancer Inst Date: 2003-06-18 Impact factor: 13.506
Authors: Jeanne S Mandelblatt; Clyde B Schechter; K Robin Yabroff; William Lawrence; James Dignam; Martine Extermann; Sarah Fox; Gretchen Orosz; Rebecca Silliman; Jennifer Cullen; Lodovico Balducci Journal: J Gen Intern Med Date: 2005-06 Impact factor: 5.128
Authors: Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Ellen M Janssen; Craig E Pollack; Cynthia Boyd; John F P Bridges; Qian-Li Xue; Antonio C Wolff; Nancy L Schoenborn Journal: Med Decis Making Date: 2019-06-21 Impact factor: 2.583
Authors: Robin B Leopold; Alexander W Thomas; Kyle F Concannon; Alissa D Correll; Catherine M LaPenta; Stephen M Maurer; Brian L Sprague; Sally D Herschorn; Claire F Verschraegen Journal: Breast Cancer Res Treat Date: 2017-03-06 Impact factor: 4.872
Authors: Young Chandler; Jinani C Jayasekera; Clyde B Schechter; Claudine Isaacs; Christopher J Cadham; Jeanne S Mandelblatt Journal: J Natl Cancer Inst Date: 2020-06-01 Impact factor: 13.506
Authors: Nancy L Schoenborn; Norah L Crossnohere; Ellen M Janssen; Craig E Pollack; Cynthia M Boyd; Antonio C Wolff; Qian-Li Xue; Jacqueline Massare; Marcela Blinka; John F P Bridges Journal: J Gen Intern Med Date: 2019-08-26 Impact factor: 5.128
Authors: Mucahit Cevik; Mehmet Ali Ergun; Natasha K Stout; Amy Trentham-Dietz; Mark Craven; Oguzhan Alagoz Journal: Med Decis Making Date: 2015-10-15 Impact factor: 2.583
Authors: Oguzhan Alagoz; Donald A Berry; Harry J de Koning; Eric J Feuer; Sandra J Lee; Sylvia K Plevritis; Clyde B Schechter; Natasha K Stout; Amy Trentham-Dietz; Jeanne S Mandelblatt Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583
Authors: Clyde B Schechter; Aimee M Near; Jinani Jayasekera; Young Chandler; Jeanne S Mandelblatt Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583
Authors: Frank van Hees; Sameer D Saini; Iris Lansdorp-Vogelaar; Sandeep Vijan; Reinier G S Meester; Harry J de Koning; Ann G Zauber; Marjolein van Ballegooijen Journal: Gastroenterology Date: 2015-08-04 Impact factor: 22.682